Price Alert

Metsera Inc. (MTSR)

NASDAQ: MTSR · Real-Time Price · USD

53.00

-0.58 (-1.08%)

At close: Sep 23, 2025, 3:59 PM

-1.08% (1D)

Bid	52.87
Market Cap	5.57B
Revenue (ttm)	n/a
Net Income (ttm)	-307.82M
EPS (ttm)	-2.94
PE Ratio (ttm)	-18.03
Forward PE	-15.09
Analyst	Buy
Dividends	n/a

Ask	53
Volume	6,395,470
Avg. Volume (20D)	1,737,319
Open	53.05
Previous Close	53.58
Day's Range	52.63 - 53.45
52-Week Range	12.30 - 54.47
Beta	0.75
Ex-Dividend Date	n/a

About MTSR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MTSR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MTSR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 days ago New

+60.8%

Metsera shares are trading higher on reports that ... Unlock content with Pro Subscription

1 month ago

-5.73%

Metsera shares are trading lower after the company reported worse-than-expected Q2 EPS results.

News

23 hours ago · zacks.com

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?

Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).

1 day ago · businesswire.com

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Met...

20 hours ago · proactiveinvestors.co.uk

Pfizer's Metsera buy raises competitive heat for Novo Nordisk

UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towa...

2 days ago · fastcompany.com

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo...

2 days ago · youtube.com

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.

1 day ago · schaeffersresearch.com

Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.

1 day ago · proactiveinvestors.com

Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline

Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. ...

1 day ago · investopedia.com

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal

Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares o...

1 day ago · cnbc.com

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move...

1 day ago · marketwatch.com

Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal

Metsera's shareholders could see significant bonuses if certain milestones are reached.

Load More News